(Q48105784)

8 February 2018

title

Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. (English)

1 reference

8 February 2018

0 references

Lichtinghagen R

1

1 reference

8 February 2018

Seifert T

2

1 reference

8 February 2018

Kracke A

3

1 reference

8 February 2018

Marckmann S

4

1 reference

8 February 2018

Wurster U

5

1 reference

8 February 2018

Heidenreich F

6

1 reference

8 February 2018

publication date

1 September 1999

1 reference

8 February 2018

Journal of Neuroimmunology

published in

1 reference

8 February 2018

volume

99

1 reference

8 February 2018

issue

1

1 reference

8 February 2018

page(s)

19-26

1 reference

8 February 2018

Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

The Expression of Tissue-type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Immunologic Mechanisms and Therapy in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Immunological aspects of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Quantitative PCR: theoretical considerations with practical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900094-6

7 January 2021

10.1016/S0165-5728(99)00094-6

Identifiers

DOI

1 reference

8 February 2018

1 reference

8 February 2018